Drug Trial Radar · NCT05518123
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
962
Actual
Start
Nov 7, 2022
Primary completion
Mar 31, 2025
Study completion Jul 8, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
Conditions
- Migraine
Interventions
RimegepantDrug
Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase
PlaceboDrug
Matching placebo with every other day dosing during DBT phase
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)Time frame: Observation phase (28 days prior to randomization), DBT phase (through Month 3 [Week 1 to 12])
Locations
111 sites in 14 countries. Site status is shown where the registry gives one.
Clinical Research Institute
Los Angeles, California
California Neuroscience Research, LLC
Sherman Oaks, California
Ki Health Partners LLC, dba New England Institute for Clinical Research
Stamford, Connecticut
Sandhill Research, LLC d/b/a Accel Research Sites Network-Edgewater Clinical Research Unit
Edgewater, Florida
Wr-Msra,Llc
Lake City, Florida
AppleMed Research Group, LLC
Miami, Florida
Sensible Healthcare LLC
Ocoee, Florida
Sandhill Research, LLC d/b/a Accel Research Sites Network - Ormond Clinical Research Unit
Ormond Beach, Florida
Boston Clinical Trials
Boston, Massachusetts
Community Clinical Research Network, Inc.
Marlborough, Massachusetts
Michigan Headache & Neurological Institute
Ann Arbor, Michigan
Rochester Medical Group
Rochester Hills, Michigan
Clinvest Research, LLC
Springfield, Missouri
St Charles Clinical Research
Weldon Spring, Missouri
Wr-Crcn, Llc
Las Vegas, Nevada
Albuquerque Clinical Trials. Inc.
Albuquerque, New Mexico
DiGiovanna Institute for Medical Education And Research
North Massapequa, New York
Headache Wellness Center, PC
Greensboro, North Carolina
Synexus Clinical Research US, Inc. - Anderson
Anderson, South Carolina
Alliance for Multispecialty Reseach, LLC
Knoxville, Tennessee
Red Star Research, LLC
Lake Jackson, Texas
DM Clinical Research
Tomball, Texas
Northwest Clinical Research Center
Bellevue, Washington
USC Clinical Trials Sunshine Coast
Sippy Downs, Queensland, Australia
Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria
Medical University Innsbruck
Innsbruck, Tyrol, Austria
GZA Ziekenhuizen
Antwerp, Belgium
AZ Sint-Jan Brugge-Oostende AV
Bruges, Belgium
Jessa Ziekenhuis
Hasselt, Belgium
Clinique de la Citadelle
Liège, Belgium
Cabinet Privé Dr. Simona Sava
Saint Nicolas Province de Liège, Belgium
UZ Brussel
Jette, Brussels Capital, Belgium
ALPHA Recherche Clinique
Québec, Canada
Aggarwal and Associates Limited
Brampton, Ontario, Canada
NeuPath Centre for Pain and Spine
Brampton, Ontario, Canada
Centre de Recherche Saint-Louis/Clinique Neuro-Levis
Lévis, Quebec, Canada
ALPHA Recherche Clinique
Québec, Quebec, Canada
University Hospital of Southern Denmark
Esbjerg, Denmark
Hospitalsenhed Midt
Viborg, Denmark
Bispebjerg Hospital
Copenhagen NV, Capital Region, Denmark
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.